In silico, 6LU7 protein inhibition using dihydroxy-3-phenyl coumarin derivatives for SARS-CoV-2

Year 2020, Volume: 7 Issue: 3, 691 - 712, 30.10.2020

Mücahit Özdemir , Baybars Köksoy , Deniz Ceyhan Mustafa Bulut , Bahattin Yalcin

https://doi.org/10.18596/jotcsa.753157

Cited By: 5

Abstract

The new emerging coronavirus (SARS-CoV-2) has become a global health problem with very rapid transmission from person to person, causing severe acute respiratory problems. In the circumstance, the discovery of vaccines or drugs to eradicate or reduce the impact of the COVID-19 has made it imperative to develop new approaches. In the current situation, many drugs on the drug bank have been researched computationally and the synthesis has not been emphasized much. We tested 42 coumarin derivatives (1a-14c) containing 14 different substituents, which are secondary metabolites of plants, and the anticoagulant coumadin (warfarin) drug as a reference by docking method on 6LU7 main protease. Optimized geometries, electron motions and energy values of all coumarins were also determined using the Density Functional Theory (DFT) method. Coumarins formed strong interactions with HIS41, CYS145 and other amino acids in the active site of the main protease. In general, 6,7-dihydroxy-3-phenylcoumarin derivatives gave relatively higher scores, and for all coumarins, biphenyl (for 10a, -8.6 kcal/mol; 10b, -8.3 kcal/mol; 10c -7.9 kcal/mol) and 4-trifluoromethylphenyl (for 13a, -8.1 kcal/mol; 13b, -8.1 kcal/mol; 13c -8.3 kcal/mol) substituted coumarin had the highest score. The coumarins data reported in this study serves as a stepping stone for in vitro and in vivo experimental research for vaccine development purposes.

Keywords

COVID-19 main protease, SARS-CoV-2, Molecular docking, Drug design, Coumarins

Thanks

The numerical calculations reported in this paper were fully performed at TUBITAK ULAKBIM, High Performance and Grid Computing Center (TRUBA resources).

References

• 1. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. International Journal of Antimicrobial Agents. 2020:105924.
• 2. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Military Medical Research. 2020;7(1):1-10.
• 3. Lu H, Stratton CW, Tang YW. Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle. Journal of Medical Virology.
• 4. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology. 2020:200490.
• 5. Singhal T. A review of coronavirus disease-2019 (COVID-19). The Indian Journal of Pediatrics. 2020:1-6.
• 6. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). Statpearls: StatPearls Publishing; 2020.
• 7. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity. 2020:102433.
• 8. Al-Tawfiq JA. Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19). Travel Medicine and Infectious Disease. 2020.
• 9. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of Internal Medicine. 2020;172(9):577-82.
• 10. Hill MA, Mantzoros C, Sowers JR. Commentary: COVID-19 in patients with diabetes. Metabolism. 2020.
• 11. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine. 2020;8(4):e21.
• 12. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nature Reviews Cardiology. 2020;17(5):259-60.
• 13. Terpos E, Ntanasis‐Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID‐19. American Journal of Hematology. 2020.
• 14. Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome. Journal of Thrombosis and Haemostasis. 2020.
• 15. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood, The Journal of the American Society of Hematology. 2020;135(23):2033-40.
• 16. Hassan MZ, Osman H, Ali MA, Ahsan MJ. Therapeutic potential of coumarins as antiviral agents. European Journal of Medicinal Chemistry. 2016;123:236-55.
• 17. Curini M, Epifano F, Maltese F, Marcotullio MC, Gonzales SP, Rodriguez JC. Synthesis of collinin, an antiviral coumarin. Australian Journal of Chemistry. 2003;56(1):59-60.
• 18. Yang G, Chen D. Biflavanones, flavonoids, and coumarins from the roots of Stellera chamaejasme and their antiviral effect on hepatitis B virus. Chemistry & Biodiversity. 2008;5(7):1419-24.
• 19. Ojala T, Remes S, Haansuu P, Vuorela H, Hiltunen R, Haahtela K, et al. Antimicrobial activity of some coumarin containing herbal plants growing in Finland. Journal of Ethnopharmacology. 2000;73(1-2):299-305.
• 20. Smyth T, Ramachandran V, Smyth W. A study of the antimicrobial activity of selected naturally occurring and synthetic coumarins. International Journal of Antimicrobial Agents. 2009;33(5):421-6.
• 21. O'reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs: initiation of warfarin therapy without a loading dose. Circulation. 1968;38(1):169-77.
• 22. O'Reilly RA, Aggeler PM, Leong LS. Studies on the coumarin anticoagulant drugs: the pharmacodynamics of warfarin in man. The Journal of Clinical Investigation. 1963;42(10):1542-51.
• 23. O’Reilly RA, Aggeler PM, Hoag MS, Leong L. Studies on the coumarin anticoagulant drugs: the assay of warfarin and its biologic application. Thrombosis and Haemostasis. 1962;8(02):082-95.
• 24. Gormley NA, Orphanides G, Meyer A, Cullis PM, Maxwell A. The interaction of coumarin antibiotics with fragments of the DNA gyrase B protein. Biochemistry. 1996;35(15):5083-92.
• 25. Maxwell A. The interaction between coumarin drugs and DNA gyrase. Molecular Microbiology. 1993;9(4):681-6.
• 26. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, et al. Gaussian 09 Revision C. 01. Wallingford CT: Gaussian, Inc.; 2009.
• 27. Dennington R, Keith T, Millam J. GaussView, version 6. 2009.
• 28. Becke AD. Density-functional exchange-energy approximation with correct asymptotic behavior. Physical Review A. 1988;38(6):3098.
• 29. Becke AD. Becke’s three parameter hybrid method using the LYP correlation functional. The Journal of Chemical Physics. 1993;98:5648-52.
• 30. Lee C, Yang W, Parr RG. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Physical Review B. 1988;37(2):785.
• 31. Kohn W, Sham LJ. Self-consistent equations including exchange and correlation effects. Physical Review. 1965;140(4A):A1133.
• 32. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry. 2010;31(2):455-61.
• 33. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry. 2009;30(16):2785-91.
• 34. BIOVIA DS. Discovery Studio Visualizer. San Diego, CA, USA. 2017.
• 35. Schrödinger. Schrödinger Release 2020-2: Maestro. LLC, New York, NY; 2020.
• 36. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports. 2017;7:42717.
• 37. Liu X, Wang X-J. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. Journal of Genetics and Genomics. 2020;47(2):119.
• 38. Benigni R, Bossa C, Tcheremenskaia O. Nongenotoxic carcinogenicity of chemicals: mechanisms of action and early recognition through a new set of structural alerts. Chemical reviews. 2013;113(5):2940-57.
• 39. Pollock BE. Clinical experience with warfarin (coumadin) sodium, a new anticoagulant. Journal of the American Medical Association. 1955;159(11):1094-7.
• 40. Nath SK, Sandhu AP, Rose BS, Simpson DR, Nobiensky PD, Wang J-Z, et al. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. International Journal of Radiation Oncology* Biology* Physics. 2010;78(2):435-41.
• 41. Keskin S, Gökmen İE, Koç O, Özbek O. Unusual complication of coumadin toxicity mimicking Crohn’s disease. Case Reports. 2014;2014:bcr2013202755.
• 42. Baer S, Yarrow MW, Kravitz C, Markson V. Clinical experiences with warfarin (coumadin) sodium as an anticoagulant. Journal of the American Medical Association. 1958;167(6):704-8.